## PODD: Insulet Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -9.6% below STRENGTH zone (4.0-10.0%); PEG 3.31 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($271.19)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. (PODD) Movement as an Input in Quant Signal Sets**
- Source: Stock Traders Daily | 20251211T104600 | Neutral | Relevance: 98%
- This article analyzes Insulet Corporation (PODD) using AI-generated quant signals, highlighting weak near and mid-term sentiment but a strong long-term outlook. It provides specific trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with entry, target, and stop-loss levels. The analysis emphasizes the importance of movement as an input for quantitative signal sets in determining risk and positioning.

**2. A Look Into Insulet Inc's Price Over Earnings**
- Source: Benzinga | 20251211T200850 | Neutral | Relevance: 98%
-  Insulet Inc. (NASDAQ: PODD) recently saw a 0.55% share price spike, though it fell 11.16% over the last month, it's up 9.73% annually. The company's P/E ratio of 86.06 is higher than the Health Care Equipment & Supplies industry's aggregate of 46.67, suggesting it might be overvalued. Investors should use the P/E ratio alongside other financial metrics for informed decisions.

**3. FDA clearances: Medtronic, Insulet, Resmed**
- Source: Modern Healthcare | 20251211T110844 | Somewhat-Bullish | Relevance: 84%
-  The FDA has cleared new medical devices from Medtronic, Insulet, and Resmed. This article briefly mentions these clearances.

**4. Did Tandem’s Insulin Pump Correction and Securities Probe Just Shift Tandem Diabetes Care's (TNDM) Investment Narrative?**
- Source: Simply Wall Street | 20251209T150953 | Neutral | Relevance: 64%
-  Tandem Diabetes Care is facing scrutiny after issuing a voluntary medical device correction for its t:slim X2 insulin pumps, leading to law firm investigations into potential misleading information provided to investors. This situation could alter the company's investment narrative and risk profile, despite ongoing product innovation like the SteadiSet seven-day infusion set. The article highlights how these events might impact investor trust and valuation, with Simply Wall St's narrative projecting significant revenue and earnings growth by 2028.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Canaccord Genui | $432 | $428 | +1% |
| 2025-11-21 | Truist Securiti | $412 | $390 | +6% |
| 2025-11-21 | RBC Capital | $380 | $370 | +3% |
| 2025-11-21 | BTIG | $380 | $370 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Canaccord Genui | main | Buy |
| 2025-11-21 | Truist Securiti | main | Buy |
| 2025-11-21 | RBC Capital | main | Outperform |
| 2025-11-21 | BTIG | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 55.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+1.0%)
- FMR, LLC: 10.8% (+0.8%)
- Blackrock Inc.: 9.4% (+2.8%)
- Capital Research Glo: 6.5% (-4.0%)
- State Street Corpora: 4.4% (+1.1%)

### Key Risks

1. Valuation stretched: PEG 3.3x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +5%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.31 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.9x). Revenue growth strong at 20% YoY. Insider buying signal ($0.5M), management confidence. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.7B |
| Beta | 1.38 |
| 52W Range | $230.05 - $354.88 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.31 |
| Forward P/E | 47.6 |
| Current P/E | 60.1 |
| YoY Growth | 26.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -8.3% to -9.6% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 13.6pp (needs >4.0% for momentum thesis). AM_20 at -7.6% indicates price below own 20MA trend. Underperforming sector by 7.3pp, stock-specific weakness. Below SMA200 (0.98x), long-term trend not supportive. MACD histogram bearish (-3.47), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -9.63% (CS: 1) | Weak |
| RSI_14 | 37.2 | Neutral |
| MACD Histogram | -3.47 | Bearish |
| vs SMA20 | 0.924x | Below |
| vs SMA50 | 0.923x | Below |
| vs SMA200 | 0.977x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $294.17
- **Stop Loss:** $271.19 (7.8% risk)
- **Target:** $317.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 60
- **Position Value:** $17,650.20
- **Portfolio %:** 17.65%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-19 (Est: $1.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.15 | $1.24 | +8.1% |
| 2025Q2 | $0.92 | $1.17 | +26.8% |
| 2025Q1 | $0.79 | $1.02 | +29.7% |
| 2024Q4 | $1.02 | $1.15 | +12.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*